61
Views
2
CrossRef citations to date
0
Altmetric
Review

Novel conjugation and combination strategies of mitomycin C with special focus on the current patent literature

&
Pages 1157-1168 | Published online: 02 Dec 2005

Bibliography

  • WAKAKI S, MARUMO H, TOMIOKA K et al.: Isolation of new fractions of antitumor mitomycins. Antibiot. Chemother. (1958) 8:228–240.
  • VERWEIJ J, PINEDO HM: Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs (1990) 1:5–13.
  • ••Excellent overview of the chemistry,mechanisms of action and the pharmacology of MMC.
  • BRANDNER WT: Mitomycin C: a clinical update. Cancer Treat. Rev. (2001) 27:35–50.
  • •Review of clinical trials with MMC published up until 2000.
  • MACKEY TA, OELKERS C, RIX U et ed.: Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J. Med. Chem. (2002) 45:1122–1127.
  • YOSHIDA S, YAMANA H, TANAKA T et al.: Effect on combination therapy with a methionine-mitomycin C conjugate and a methionine-deficient diet on tumor growth. In vivo (1998) 12:351–356.
  • LEE SH, KOHN H: 7-N, 7'-N'-(1",2"-dithiany1-3",6"-dimethylenyl)bismitomycin C: synthesis and nucleophilic activation of a dimeric mitomycin. Org Biol. Chem. (2005) 3:471–482.
  • SHIKANO M, ONIMURA K, FUKAI Yet al.: la-Docosahexaenoyl mitomycin C: a novel inhibitor of protein tyrosine kinase. Biochem. Biophys. Res. Comm. (1998) 248:858–863.
  • KAMIZURU H, KIMURA H, YASUKAWA T et al.: Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. /OVS (2001) 42:2664–2672.
  • LI H, LIU Y, SHU XZ et al.: Synthesis and biological evaluation of a cross-linked hyaluronan-mitomycin C hydrogel. Biomacromolecules (2004) 5:895–902.
  • ••Interesting development especially for thenon-oncologic use of MMC.
  • KATO Y, ONISHI H, MACHIDA Y: N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates. Biomaterials (2004) 25:907–915.
  • KAMIYAMA K, ONISHI H, MACHIDAY: Biodisposition characteristics of N-succinyl-chitosan and glykol-chitosan in normal and tumor-bearing mice. Biol. Pharm. Bull. (1999) 22:179–186.
  • KATO Y, ONISHI H, MACHIDA Y: Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis. Int. J. Pharm. (2001) 226:93–106.
  • ONISHI H, TAKAHASHI H, YOSHIYASU M, MACHIDA Y: Preparation and in vitro properties of N-succinylchitosan- or carboxymethylchitin-mitomycin C conjugate microparticles with specified size. DrugDev. Ind. Pharm. (2001) 27:659–667.
  • MAISEY N, CHAU I, CUNNINGHAM D et al.: Multicenter randomized Phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. Clin. Oncol (2002) 20:3130–3136.
  • ROSS P, NORMAN A, CUNNINGHAM D A et al.: Prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann. Oncol (1997) 8:995–1001.
  • DE PLACIDO S, LAURIA R, PERRONE F et al.: Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage Phase II study. Oncology (2000) 58:8–14.
  • KRUCZYNSKI A, HILL1BT: Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit. Rev. Oncol Hematol (2001) 40:159–173.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.